Key Highlights

  • Microbot Medical (NASDAQ:MBOT) traded at USD 1.10, up 6.80%, in pre-market trading on Wednesday, October 28, 2026. No announcement dated that day or the one before was identified, and the most recent release was a patent notice of Tuesday, October 20, 2026.
  • Second quarter 2026 revenue was USD 241,000 against cost of revenue of USD 884,000, and the net loss reached USD 5.6 million, according to the Form 10-Q for the quarter ended Tuesday, June 30, 2026.
  • Cash, cash equivalents and marketable securities together totalled about USD 67.4 million at Tuesday, June 30, 2026. Management said that sum is enough to fund operations for more than twelve months from the filing.
  • The company is aiming for 12 sales territories by year-end and a CE Mark, a European conformity approval, in late 2026 or early 2027. Pre-market prices are thin and can change before the open.

Pre-Market Move and Its Trigger

Microbot Medical (NASDAQ:MBOT) sells the LIBERTY endovascular robotic system, a single-use robot used to navigate blood vessels. Its pre-market quote of USD 1.10, up 6.80%, came on Wednesday, October 28, 2026, and it can change before the 9:30 a.m. ET open. The company issued no release dated that day or the one before. Its most recent news, from Tuesday, October 20, 2026, announced new patents in the United States, Japan, China and Canada, bringing the portfolio to 44 issued patents and 49 pending applications. A move that reflects interest in the commercial rollout and thin liquidity is consistent with the quote, though neither point is confirmed as the cause.

How the Quarterly Figures Frame the Move

What matters most is that revenue is only just getting started. The Form 10-Q for the quarter ended Tuesday, June 30, 2026, filed on Tuesday, August 11, 2026, showed second quarter revenue of USD 241,000 and six month revenue of USD 346,000. Cost of revenue was USD 884,000 in the quarter, so costs outran sales, a simple comparison of two published numbers. The net loss was USD 5.6 million for the quarter and USD 9.3 million for the half year. Cash and equivalents of about USD 3.2 million plus marketable securities of about USD 64.2 million added up to roughly USD 67.4 million. The company said revenue and customer count each more than doubled against the first quarter, and that its territories grew from four to eight.

Risks and Signals to Track

The positive case depends on the commercial ramp, an exclusive three-year distribution agreement for Israel signed on Tuesday, October 6, 2026 with initial orders expected in the fourth quarter, a first California customer and a well-funded balance sheet. The negative case centres on very small revenue, a negative gross margin that the company does not expect to turn positive until 2027, and continuing losses. Named risks include dilution through an at-the-market programme that lets the company sell shares into the market, regional conflict affecting Israel-based operations and execution at a second manufacturing site. Investors should watch the CE Mark decision, the third quarter filing, which has no announced date, and the Federal Reserve decision due later on Wednesday, October 28, 2026.

Where Things Stand

The short answer is that Microbot Medical (NASDAQ:MBOT) rose 6.80% before the open without a dated announcement. The commercial rollout and thin trading are the readings that fit best. The headline number is about USD 67.4 million of cash and marketable securities, which compares with second quarter revenue of only USD 241,000. The next catalysts are the first Israel orders expected in the fourth quarter of 2026, the CE Mark expected in late 2026 or early 2027 and the Federal Reserve decision due later on Wednesday, October 28, 2026. Pre-market prices are snapshots and can change, and this is not investment advice.